SCHEMBL2311460

SCHEMBL2311460

CC(C)n1cnc2c(NCCNc3ccccn3)nc(-c3cccnc3)nc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 3/20 0.55
▸ CDK12 Q9NYV4 3/20 0.55
▸ CDK2 P24941 12/20 0.50
▸ CDK5 Q00535 11/20 0.50
▸ CDK5R1 Q15078 11/20 0.50
▸ CCNA2 P20248 7/20 0.50
▸ CCNA1 P78396 7/20 0.50
▸ DYRK1A Q13627 6/20 0.50
▸ CDK1 P06493 9/20 0.48
▸ CCNB1 P14635 8/20 0.48
▸ CCNB2 O95067 5/20 0.48
▸ CCNB3 Q8WWL7 5/20 0.48
▸ CDK9 P50750 2/20 0.47
▸ CCNE1 P24864 4/20 0.46
▸ CCNE2 O96020 1/20 0.46
▸ CDK4 P11802 4/20 0.45
▸ MAPK1 P28482 4/20 0.45
▸ CDK7 P50613 4/20 0.45
▸ CCND1 P24385 3/20 0.45
▸ CCNH P51946 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30315420 1.00 CCNK (0.55) CCNKCDK12CDK2CDK5CDK5R1
SCHEMBL21017207 0.85 CDK2 (0.52) CCNKCDK12CDK2CDK5CDK5R1
SCHEMBL2315371 0.84 CDK2 (0.54) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL2318356 0.83 AHR (0.51) CCNKCDK12CDK2CDK5CDK5R1
SCHEMBL2310970 0.83 CDK5 (0.53) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL30315332 0.83 CDK5 (0.53) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL20895840 0.81 AHR (0.49) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL2317564 0.81 AHR (0.62) CDK2CDK5CDK5R1CCNA2CCNA1
SCHEMBL3501809 0.81 AHR (0.51) CCNKCDK12CDK2CDK5CDK5R1
SCHEMBL25306155 0.80 CDK2 (0.51) CCNKCDK12CDK2CDK5CDK5R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US claimed
EP-2350078-B1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2019-04-17 — — EP claimed
US-20170239296-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2017-08-24 — — US claimed
US-9580426-B2 Compounds that expand hematopoietic stem cells NOVARTIS AG (CH) 2017-02-28 — — US claimed
US-9175266-B2 Enhancement of natural killer (NK) cell proliferation and activity GAMIDA CELL LTD. (IL) 2015-11-03 — — US claimed
US-8927281-B2 Method for expanding hematopoietic stem cells IRM LLC (BM) 2015-01-06 — — US claimed
US-20140114070-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS THE SCRIPPS RESEARCH INSTITUTE (US) 2014-04-24 — — US claimed
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby GAMIDA CELL INC. 2014-01-23 — — US claimed
US-20140023626-A1 Enhancement of Natural Killer (NK) Cell Proliferation and Activity GAMIDA CELL INC. 2014-01-23 — — US claimed
EP-2350078-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2011-08-03 — — EP claimed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US claimed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO claimed
EP-3524604-B1 EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE NOVARTIS AG (CH) 2023-03-29 — — EP disclosed
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US disclosed
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS NOVARTIS AG (CH) 2021-06-24 — — US disclosed
EP-3524604-A1 EXPANDED HEMATOPOIETIC STEM CELLS FROM CORD BLOOD AND THEIR THERAPEUTIC USE Novartis AG (CH) 2019-08-14 — — EP disclosed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US disclosed
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-07-22 — — US disclosed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO disclosed
WO-2010059401-A2 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS IRM LLC (BM) 2010-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170239296-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 CCNK 2896/4885CDK12 2618/4885CDK2 3659/4885
US-20210187033-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 CCNK 2896/4885CDK12 2618/4885CDK2 3659/4885
US-20140114070-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 CCNK 2896/4885CDK12 2618/4885CDK2 3659/4885
US-20140023626-A1 Enhancement of Natural Killer (NK) Cell Proliferation and Activity PBK, IL2, AHR CCNK 211/4885CDK12 1748/4885CDK2 1909/4885
US-20100183564-A1 COMPOUNDS THAT EXPAND HEMATOPOIETIC STEM CELLS CD47, HCLS1, CD74 CCNK 2896/4885CDK12 2618/4885CDK2 3659/4885
US-20140023623-A1 Methods of Culturing and Expanding Mesenchymal Stem Cells and Isolated Cell Populations Generated Thereby AHR, HGF, MTNR1A CCNK 3442/4885CDK12 4424/4885CDK2 2032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback